Plain-English translation of NCT06681623 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a medication called to see how well it works and how safe it is for older adults with relapsing multiple sclerosis (a type of MS where symptoms come and go). Most previous studies of this medication excluded people over 55, so this research is filling that gap by specifically studying how the medication works in adults between ages 55 and 80.
Older adults with relapsing MS were left out of the early research on this medication, so doctors don't have enough information about how well it works or what side effects to expect in this age group. This study will help doctors understand whether and how safely this treatment can be used for older patients.
You likely qualify if…
You likely don't qualify if…
You would take as prescribed by your doctor while being closely monitored over 24 months. You'll visit the study center about 6 times during this period so researchers can check on your health, watch for any side effects (especially infections), and measure how well the medication is working. The main focus is making sure the treatment is safe and that you're tolerating it well.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Sponsor
Neurology Center of New England P.C.
Enrollment target
~20 participants
Started
August 2024
Primary completion
September 2027
Age range
55 Years – 80 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Salvatore Napoli, MD
Neurology Center of New England P.C.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.